Who are electroCore, Inc.'s main suppliers?

electroCore, Inc. (ECOR) key suppliers include: Eli Lilly and Company, Eli Lilly and Company. View the full supplier network at chainsifter.com/chain/ECOR.

Who are electroCore, Inc.'s major customers?

electroCore, Inc. (ECOR) key customers include: USGOV-DEPARTMENT-OF-DEFENSE, LOVELL, UNITED-STATES-DEPARTMENT-OF-VETERANS-AFFAIRS, VA-FACILITIES, NHS-ENGLAND and 3 more. View the full customer network at chainsifter.com/chain/ECOR.

What sector is electroCore, Inc. in?

electroCore, Inc. (ECOR) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

ECOR Supply Chain: electroCore, Inc. Suppliers & Customers

2Suppliers

8Customers

3Debt Items

20Related Chains

electroCore, Inc. Suppliers

Ticker	Name	Confidence	Evidence
LLY	Eli Lilly and Company	72%	uster and migraine markets by securing broad market acceptance of our prescription gammaCore therapy. We believe that the primary competitive factors in the primary headache markets including those f…
LLY	Eli Lilly and Company	72%	Reciprocal relationship from LLY graph: Reciprocal relationship from ECOR graph: Reciprocal relationship from LLY graph: Reciprocal relationship from ECOR graph: Reciprocal relationship from LLY grap…

electroCore, Inc. Customers

Ticker	Name	Confidence	Evidence
USGOV-DEPARTMENT-OF-DEFENSE	USGOV-DEPARTMENT-OF-DEFENSE	95%	USAspending awards from Department of Defense: $210,180 across 3 awards. W911S225PA206 SOLICITATION W911S225U0337: TAC-STIM; FA300225P0015 THE REQUIREMENT IS FOR TWELVE (12) TAC-STIM NON-INVASIVE VAG…
LOVELL	LOVELL	92%	We expect an increasing portion of our 2026 sales will be made pursuant to the non-exclusive distribution agreement with Lovell, and its contract vehicles, concentrating our customer base even furthe…
UNITED-STATES-DEPARTMENT-OF-VETERANS-AFFAIRS	UNITED-STATES-DEPARTMENT-OF-VETERANS-AFFAIRS	92%	The Company earns a significant amount of its revenue in the United States from the United States Department of Veterans Affairs, or VA, channel pursuant to its qualifying contract under the Federal …
VA-FACILITIES	VA-FACILITIES	92%	During the years ended December 31, 2025 and 2024, revenue from VA facilities pursuant to the terms and conditions of our qualifying contract under the FSS and open market sales represented 71.2% and…
NHS-ENGLAND	NHS-ENGLAND	85%	any changes in recommendation or pricing may adversely impact our ability to work with NHS England on the MTFM program, which could have an adverse impact on our business in the United Kingdom.
UNITED-KINGDOM-NATIONAL-HEALTH-SERVICE	UNITED-KINGDOM-NATIONAL-HEALTH-SERVICE	85%	During the three months ended March 31, 2026 and 2025, one facility accounted for more than 10% of net sales from the United Kingdom National Health Service ("NHS").
LLY	Eli Lilly and Company	72%	uster and migraine markets by securing broad market acceptance of our prescription gammaCore therapy. We believe that the primary competitive factors in the primary headache markets including those f…
LLY	Eli Lilly and Company	72%	Reciprocal relationship from LLY graph: Reciprocal relationship from ECOR graph: uster and migraine markets by securing broad market acceptance of our prescription gammaCore therapy. We believe that …

electroCore, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
ECOR-DEBT-9217	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2023-12-31.
ECOR-DEBT-9216	Warrants outstanding: 44000	90%	xbrl warrant detail from xbrl 2026-04-30.
ECOR-DEBT	Debt stack $9.5M	90%	Market cache reports total debt of $9.5M.

electroCore, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for electroCore, Inc..

electroCore, Inc. Ownership

No ownership data on recordNo major institutional ownership relationships found in our database for electroCore, Inc..

electroCore, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
LLY	Eli Lilly and Company	100.00	1	['customer', 'supplier']
LOVELL	LOVELL	63.48	1	['receiving']
DAWN	Day One Biopharmaceuticals Inc	50.00	2
BIOA	BioAge Labs, Inc.	50.00	2
FHTX	Foghorn Therapeutics Inc.	50.00	2
DSGN	Design Therapeutics, Inc.	50.00	2
EDSA	Edesa Biotech, Inc.	50.00	2
ELAN	Elanco Animal Health Incorporated	50.00	2
BCYC	Bicycle Therapeutics plc	50.00	2
LGND	Ligand Pharmaceuticals Incorporated	50.00	2
AMPH	Amphastar Pharmaceuticals, Inc.	50.00	2
NVO	Novo Nordisk A/S	50.00	2
GYRE	Gyre Therapeutics, Inc.	50.00	2
SDGR	Schrödinger, Inc.	50.00	2
ALNY	Alnylam Pharmaceuticals, Inc.	50.00	2
AKTS	Aktis Oncology, Inc.	50.00	2
CRNX	Crinetics Pharmaceuticals, Inc.	50.00	2
CAH	Cardinal Health, Inc.	50.00	2
VNDA	Vanda Pharmaceuticals Inc.	50.00	2
AXSM	Axsome Therapeutics, Inc.	50.00	2

electroCore, Inc. Supply Chain